Loading...
The CDC recommends antivirals for managing influenza in patients with severe illness or those at excess risk for complications. In a meta-analysis of 73 randomized clinical trials, investigators examined use of antivirals for those with nonsevere influenza (median age, 35). The study considered illness duration, hospitalization, mortality, adverse events, and emergence of resistance.
In 65 of the trials, treatment was initiated within 2 days of symptom onset. Time to alleviation of symptoms was shortened by 1 day and 0.75 days for baloxavir and oseltamivir, respectively. Oseltamivir (but not baloxavir) was associated with an increase in treatment-related adverse events. Drug resistance emerged in about 10% of baloxavir recipients (data were …